Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques最新文献_第7页

Use of vanilloids in urologic disorders. 香兰素类药物在泌尿系统疾病中的应用。

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques Pub Date : 2014-01-01 DOI: 10.1007/978-3-0348-0828-6_13

Harris E Foster, AeuMuro G Lake

{"title":"Use of vanilloids in urologic disorders.","authors":"Harris E Foster, AeuMuro G Lake","doi":"10.1007/978-3-0348-0828-6_13","DOIUrl":"https://doi.org/10.1007/978-3-0348-0828-6_13","url":null,"abstract":"The bladder is an organ rich in vanilloid targets: dense unmyelinated c-fibers partially responsible for bladder sensation and response to noxious stimuli. Drugs such as capsaicin and resiniferatoxin (RTX) interact with the VR1 vanilloid receptor subtype to initially excite then subsequently desensitize the c-fibers. This chapter examines the literature describing the use of vanilloid receptor agonists in the treatment of the following urological disorders: neurogenic bladder (NGB), overactive bladder (OAB), and interstitial cystitis/painful bladder syndrome (IC/PBS). Review of the literature was performed using Pubmed and the following key words \"capsaicin,\" \"resiniferatoxin (RTX),\" and \"neurogenic bladder,\" \"overactive bladder (OAB),\" and \"interstitial cystitis,\" \"painful bladder syndrome.\" Articles focusing on randomized trials comparing intravesical administration of a vanilloid receptor agonist to placebo and those in English were reviewed. We conclude that capsaicin and RTX do appear to provide some acceptable treatment results in patients with neurogenic bladder, though larger studies are needed to confirm this. Although efficacy has been shown in some studies, currently the use of vanilloids cannot be recommended for routine use in patients with OAB as the need for catheterization may cause the risk to outweigh the benefit of treatment. Similarly, for the treatment of BPS, vanilloid receptor agonists lack strong evidence for efficacy or tolerability; larger studies are needed to define their role. Understanding how vanilloids are able to impact these disorders, however, may help further elucidate their underlying pathophysiological processes.","PeriodicalId":20603,"journal":{"name":"Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques","volume":"68 ","pages":"307-17"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32435152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

The kallikrein-kinin pathways in hypertension and diabetes. 高血压和糖尿病的钾likrein-激肽通路。

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques Pub Date : 2014-01-01 DOI: 10.1007/978-3-319-06683-7_2

J. N. Sharma, Parvathy S Narayanan

引用次数: 16

Capsaicin-based therapies for pain control. 辣椒素为基础的疼痛控制疗法。

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques Pub Date : 2014-01-01 DOI: 10.1007/978-3-0348-0828-6_5

Howard Smith, John R Brooks

引用次数: 46

The potential antitumor effects of capsaicin. 辣椒素潜在的抗肿瘤作用。

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques Pub Date : 2014-01-01 DOI: 10.1007/978-3-0348-0828-6_8

Inés Díaz-Laviada, Nieves Rodríguez-Henche

引用次数: 77

The role of capsaicin in dermatology. 辣椒素在皮肤病学中的作用。

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques Pub Date : 2014-01-01 DOI: 10.1007/978-3-0348-0828-6_12

Katherine Boyd, Sofia M Shea, James W Patterson

引用次数: 26

TRPV1 in the central nervous system: synaptic plasticity, function, and pharmacological implications. TRPV1在中枢神经系统中的作用:突触可塑性、功能和药理意义。

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques Pub Date : 2014-01-01 DOI: 10.1007/978-3-0348-0828-6_3

Jeffrey G Edwards

{"title":"TRPV1 in the central nervous system: synaptic plasticity, function, and pharmacological implications.","authors":"Jeffrey G Edwards","doi":"10.1007/978-3-0348-0828-6_3","DOIUrl":"https://doi.org/10.1007/978-3-0348-0828-6_3","url":null,"abstract":"The function of TRPV1 in the peripheral nervous system is increasingly being investigated for its anti-inflammatory and antinociceptive properties in an effort to find a novel target to fight pain that is nonaddictive. However, in recent years, it was discovered that TRPV1 is also associated with a wide array of functions and behaviors in the central nervous system, such as fear, anxiety, stress, thermoregulation, pain, and, more recently, synaptic plasticity, the cellular mechanism that allows the brain to adapt to its environment. This suggests a new role for brain TRPV1 in areas such as learning and memory, reward and addiction, and development. This wide array of functional aspects of TRPV1 in the central nervous system (CNS) is in part due to its multimodal form of activation and highlights the potential pharmacological implications of TRPV1 in the brain. As humans also express a TRPV1 homologue, it is likely that animal research will be translational to humans and therefore worthy of exploration. This review outlines the basic expression patterns of TRPV1 in the CNS along with what is known regarding its signaling mechanisms and its role in the aforementioned brain functions. As TRPV1 involvement in synaptic plasticity has never been fully reviewed elsewhere, it will be a focus of this review. The chapter concludes with some of the potential pharmaceutical implications of further TRPV1 research.","PeriodicalId":20603,"journal":{"name":"Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques","volume":"68 ","pages":"77-104"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-3-0348-0828-6_3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32434178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 76

Renal (tissue) kallikrein-kinin system in the kidney and novel potential drugs for salt-sensitive hypertension. 肾(组织)钾化钾素-激肽系统及治疗盐敏感性高血压的新药物。

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques Pub Date : 2014-01-01 DOI: 10.1007/978-3-319-06683-7_4

Makoto Katori, Masataka Majima

{"title":"Renal (tissue) kallikrein-kinin system in the kidney and novel potential drugs for salt-sensitive hypertension.","authors":"Makoto Katori, Masataka Majima","doi":"10.1007/978-3-319-06683-7_4","DOIUrl":"https://doi.org/10.1007/978-3-319-06683-7_4","url":null,"abstract":"A large variety of antihypertensive drugs, such as angiotensin converting enzyme inhibitors, diuretics, and others, are prescribed to hypertensive patients, with good control of the condition. In addition, all individuals are generally believed to be salt sensitive and, thus, severe restriction of salt intake is recommended to all. Nevertheless, the physiological defense mechanisms in the kidney against excess salt intake have not been well clarified. The present review article demonstrated that the renal (tissue) kallikrein-kinin system (KKS) is ideally situated within the nephrons of the kidney, where it functions to inhibit the reabsorption of NaCl through the activation of bradykinin (BK)-B2 receptors localized along the epithelial cells of the collecting ducts (CD). Kinins generated in the CD are immediately inactivated by two kidney-specific kinin-inactivating enzymes (kininases), carboxypeptidase Y-like exopeptidase (CPY), and neutral endopeptidase (NEP). Our work demonstrated that ebelactone B and poststatin are selective inhibitors of these kininases. The reduced secretion of the urinary kallikrein is linked to the development of salt-sensitive hypertension, whereas potassium ions and ATP-sensitive potassium channel blockers ameliorate salt-sensitive hypertension by accelerating the release of renal kallikrein. On the other hand, ebelactone B and poststatin prolong the life of kinins in the CD after excess salt intake, thereby leading to the augmentation of natriuresis and diuresis, and the ensuing suppression of salt-sensitive hypertension. In conclusion, accelerators of the renal kallikrein release and selective renal kininase inhibitors are both novel types of antihypertensive agents that may be useful for treatment of salt-sensitive hypertension.","PeriodicalId":20603,"journal":{"name":"Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques","volume":"69 ","pages":"59-109"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-3-319-06683-7_4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32591042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

The kallikrein-kinin system in diabetic retinopathy. 糖尿病视网膜病变的激肽-激肽系统。

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques Pub Date : 2014-01-01 DOI: 10.1007/978-3-319-06683-7_5

Menakshi Bhat, Mylène Pouliot, Réjean Couture, Elvire Vaucher

{"title":"The kallikrein-kinin system in diabetic retinopathy.","authors":"Menakshi Bhat, Mylène Pouliot, Réjean Couture, Elvire Vaucher","doi":"10.1007/978-3-319-06683-7_5","DOIUrl":"https://doi.org/10.1007/978-3-319-06683-7_5","url":null,"abstract":"Diabetic retinopathy (DR) is a major microvascular complication associated with type 1 and type 2 diabetes mellitus, which can lead to visual impairment and blindness. Current treatment strategies for DR are mostly limited to laser therapies, steroids, and anti-VEGF agents, which are often associated with unwanted side effects leading to further complications. Recent evidence suggests that kinins play a primary role in the development of DR through enhanced vascular permeability, leukocytes infiltration, and other inflammatory mechanisms. These deleterious effects are mediated by kinin B1 and B2 receptors, which are expressed in diabetic human and rodent retina. Importantly, kinin B1 receptor is virtually absent in sane tissue, yet it is induced and upregulated in diabetic retina. These peptides belong to the kallikrein-kinin system (KKS), which contains two separate and independent pathways of regulated serine proteases, namely plasma kallikrein (PK) and tissue kallikrein (TK) that are involved in the biosynthesis of bradykinin (BK) and kallidin (Lys-BK), respectively. Hence, ocular inhibition of kallikreins or antagonism of kinin receptors offers new therapeutic avenues in the treatment and management of DR. Herein, we present an overview of the principal features and known inflammatory mechanisms associated with DR along with the current therapeutic approaches and put special emphasis on the KKS as a new and promising therapeutic target due to its link with key pathways directly associated with the development of DR.","PeriodicalId":20603,"journal":{"name":"Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques","volume":"69 ","pages":"111-43"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-3-319-06683-7_5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32591043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 38

Topical capsaicin formulations in the management of neuropathic pain. 局部辣椒素制剂在神经性疼痛治疗中的应用。

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques Pub Date : 2014-01-01 DOI: 10.1007/978-3-0348-0828-6_4

Mark Schumacher, George Pasvankas

{"title":"Topical capsaicin formulations in the management of neuropathic pain.","authors":"Mark Schumacher, George Pasvankas","doi":"10.1007/978-3-0348-0828-6_4","DOIUrl":"https://doi.org/10.1007/978-3-0348-0828-6_4","url":null,"abstract":"This chapter reviews the scientific and clinical evidence supporting the use of topical formulations containing the pungent principle of chili peppers--capsaicin, for the treatment of peripheral neuropathic pain. Given the limitations of current oral and parenteral therapies for the management of pain arising from various forms of nerve injury, alternate therapeutic approaches that are not associated with systemic adverse events that limit quality of life, impair function, or threaten respiratory depression are critically needed. Moreover, neuropathic conditions can be complicated by progressive changes in the central and peripheral nervous system, leading to persistent reorganization of pain pathways and chronic neuropathic pain. Recent advances in the use of high-dose topical capsaicin preparations hold promise in managing a wide range of painful conditions associated with peripheral neuropathies and may in fact help reduce suffering by reversing progressive changes in the nervous system associated with chronic neuropathic pain conditions.","PeriodicalId":20603,"journal":{"name":"Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques","volume":"68 ","pages":"105-28"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-3-0348-0828-6_4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32433002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

Foreword. Recent developments in the regulation of kinins. 前言。kinins调控的最新进展。

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques Pub Date : 2014-01-01

J N Sharma, K D Rainsford

引用次数: 0